ISSN (print) 1997-6933     ISSN (online) 2500-2139
Том 16 № 3 (2023), ОСЛОЖНЕНИЯ ПРОТИВООПУХОЛЕВОГО ЛЕЧЕНИЯ
Том 16 № 3 (2023)
ОСЛОЖНЕНИЯ ПРОТИВООПУХОЛЕВОГО ЛЕЧЕНИЯ

Новые подходы к оценке сердечно-сосудистой токсичности у пациентов с гематологическими злокачественными опухолями (обзор литературы)

Опубликовано 20.02.2024
О.Е. Данилова
ФГБОУ ВО «Самарский государственный медицинский университет» Минздрава России, ул. Чапаевская, д. 89, Самара, Российская Федерация, 443099
Гелия Рифкатовна Гиматдинова
ФГБОУ ВО «Самарский государственный медицинский университет» Минздрава России, ул. Чапаевская, д. 89, Самара, Российская Федерация, 443099
И.Л. Давыдкин
ФГБОУ ВО «Самарский государственный медицинский университет» Минздрава России, ул. Чапаевская, д. 89, Самара, Российская Федерация, 443099
О.В. Терешина
ФГБОУ ВО «Самарский государственный медицинский университет» Минздрава России, ул. Чапаевская, д. 89, Самара, Российская Федерация, 443099
В.Д. Сабанова
ФГБОУ ВО «Самарский государственный медицинский университет» Минздрава России, ул. Чапаевская, д. 89, Самара, Российская Федерация, 443099
Г.И. Давыдкин
ФГБОУ ВО «Самарский государственный медицинский университет» Минздрава России, ул. Чапаевская, д. 89, Самара, Российская Федерация, 443099
2023-3
PDF_2023-16-3_331-336

Ключевые слова

кардиотоксичность
кардиоонкология
онкология
сердечно-сосудистые осложнения
химиотерапия

Как цитировать

Данилова О.Е., Гиматдинова Г.Р., Давыдкин И.Л., Терешина О.В., Сабанова В.Д., Давыдкин Г.И. Новые подходы к оценке сердечно-сосудистой токсичности у пациентов с гематологическими злокачественными опухолями (обзор литературы). Клиническая онкогематология. 2024;(3):331–336. doi:10.21320/2500-2139-2023-16-3-331-336.
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver AMA ГОСТ

Скачать ссылку

Endnote/Zotero/Mendeley (RIS) BibTeX

Ключевые слова

Аннотация

Начиная с 2016 г. управление сердечно-сосудистыми осложнениями регламентируется рядом документов, которые основаны на рекомендациях Европейского общества кардиологов и регулярно обновляются. В настоящем обзоре литературы представлены алгоритмы диагностики и коррекции нежелательных явлений со стороны сердечно-сосудистой системы, возникающих на фоне или после проведения противоопухолевой лекарственной терапии у пациентов с гематологическими злокачественными опухолями. Цель настоящей публикации заключается в анализе данных литературы, посвященных оптимизации ведения пациентов, находящихся на противоопухолевом лечении, возможностям по улучшению качества их жизни, а также снижению летальности от сердечно-сосудистых осложнений лекарственной терапии.

PDF_2023-16-3_331-336

Библиографические ссылки

  1. Статистические данные по заболеваемости в Российской Федерации (электронный документ). Доступно по: https://rosstat.gov.ru/ Ссылка активна на 12.04.2023.
  2. [Statistical data on morbidity in the Russian Federation (Internet). Available from: https://rosstat.gov.ru/ Accessed 04.2023. (In Russ)]
  3. Sung H, Ferlay J, Siegel R, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49. doi: 10.3322/caac.21660.
  4. Kalsbeek R, Mulder R, Skinner R. The Concept of Cancer Survivorship and Models for Long-Term Follow-Up. Front Horm Res. 2021;54:1–15. doi: 10.1159/000514693.
  5. Lancellotti P, Suter T, Lopez-Fernandez T, et al. Cardio-Oncology Services: rationale, organization, and implementation. Eur Heart J. 2019;40(22):1756–63. doi: 10.1093/eurheartj/ehy453.
  6. Gilchrist S, Barac A, Ades P. Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientific Statement from the American Heart Association. Circulation. 2019;139(21):e997–e1012. doi: 10.1161/CIR.0000000000000679.
  7. Visseren F, Mach F, Smulders Y, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–337. doi: 10.1093/eurheartj/ehab484.
  8. Pareek N, Cevallos J, Moliner P, et al. Activity and outcomes of a cardio-oncology service in the United Kingdom-a five-year experience. Eur J Heart Fail. 2018;20(12):1721–31. doi: 10.1002/ejhf.1292.
  9. Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020;17(8):474–502. doi: 10.1038/s41569-020-0348-1.
  10. Herrmann J. Vascular toxic effects of cancer therapies. Nat Rev Cardiol. 2020;17(8):503–22. doi: 10.1038/s41569-020-0347-2.
  11. Armenian S, Lacchetti C, Barac A, et al. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35(8):893–911. doi: 10.1200/JCO.2016.70.5400.
  12. Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171–90. doi: 10.1016/j.annonc.2019.10.023.
  13. Lyon A, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22(11):1945–60. doi: 10.1002/ejhf.1920.
  14. McDonagh T, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726. doi: 10.1093/eurheartj/ehab368.
  15. Caro-Codon J, Lopez-Fernandez T, Alvarez-Ortega C, et al. Cardiovascular risk factors during cancer treatment. Prevalence and prognostic relevance: insights from the CARDIOTOX registry. Eur J Prev Cardiol. 2022;29(6):859–68. doi: 10.1093/eurjpc/zwaa034.
  16. Koene R, Prizment A, Blaes A, et al. Shared Risk Factors in Cardiovascular Disease and Cancer. Circulation. 2016;133(11):1104–14. doi: 10.1161/CIRCULATIONAHA.115.020406.
  17. Zamorano J, Gottfridsson C, Asteggiano R, et al. The cancer patient and cardiology. Eur J Heart Fail. 2020;22(12):2290–309. doi: 10.1002/ejhf.1985.
  18. Lopez-Sendon J, Alvarez-Ortega C, Aunon O, et al. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J. 2020;41(18):1720–9. doi: 10.1093/eurheartj/ehaa006.
  19. Holtermann A, Marott J, Gyntelberg F, et al. Self-reported cardiorespiratory fitness: prediction and classification of risk of cardiovascular disease mortality and longevity—a prospective investigation in the Copenhagen City Heart Study. J Am Heart Assoc. 2015;4(1):e001495. doi: 10.1161/JAHA.114.001495.
  20. Wickramasinghe C, Ayers C, Das S, et al. Prediction of 30-year risk for cardiovascular mortality by fitness and risk factor levels: the Cooper Center Longitudinal Study. Circ Cardiovasc Qual Outcomes. 2014;7(4):597–602. doi: 10.1161/CIRCOUTCOMES.113.000531.
  21. Pituskin E, Mackey J, Koshman S. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. J Clin Oncol. 2017;35(8):870–7. doi: 10.1200/JCO.2016.68.7830.
  22. Lyon A, Lopez-Fernandez T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229–361. doi: 10.1093/eurheartj/ehac244.
  23. NIH, National Cancer Institute, Department of Cancer Treatment and Diagnosis (Internet). Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm (accessed04.2023).
  24. Herrmann J, Yang E, Iliescu C, et al. Vascular Toxicities of Cancer Therapies: The Old and the New—An Evolving Avenue. Circulation. 2016;133(13):1272–89. doi: 10.1161/CIRCULATIONAHA.115.018347.
  25. Ferdinandy P, Baczko I, Bencsik P, et al. Definition of hidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinical implications. Eur Heart J. 2019;40(22):1771–7. doi: 10.1093/eurheartj/ehy365.
  26. Lopez-Fernandez T, Garcia AM, Beltran AS, et al. Cardio-onco-hematology in clinical practice. Position paper and recommendations. Rev. Espanola Cardiol (Engl Ed). 2017;70(6):474–86. doi: 10.1016/j.rec.2016.12.041.
  27. Shah C, Moreb J. Cardiotoxicity due to targeted anticancer agents: a growing challenge. Ther Adv Cardiovasc Dis. 2019;13:1753944719843435. doi: 10.1177/1753944719843435.
  28. Lyman G, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927–74. doi: 10.1182/bloodadvances.2020003442.
  29. Alexandre J, Salem J, Moslehi J, et al. Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database. Eur Heart J Cardiovasc Pharmacother. 2021;7(4):312–20. doi: 10.1093/ehjcvp/pvaa037.
  30. Liu J, Barac A, Thavendiranathan P, et al. Strain Imaging in Cardio-Oncology. JACC CardioOncol. 2020;2(5):677–89. doi: 10.1016/j.jaccao.2020.10.011.
  31. Eschenhagen T, Force T, Ewer M. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2011;13(1):1–10. doi: 10.1093/eurjhf/hfq213.
  32. Lapinskas T, Hireche-Chikaoui H, Zieschang V, et al. Effect of comprehensive initial training on the variability of left ventricular measures using fast-SENC cardiac magnetic resonance imaging. Sci Rep. 2019;9(1):12223. doi: 10.1038/s41598-019-48685-1.
  33. Yancy C, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137–e161. doi: 10.1161/CIR.0000000000000509.
  34. Ghatalia P, Morgan C, Je Y, et al. Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Crit Rev Oncol Hematol. 2015;94(2):228–37. doi: 10.1016/j.critrevonc.2014.12.008.
  35. Buza V, Rajagopalan B, Curtis AВ. Cancer Treatment–Induced Arrhythmias. Focus on Chemotherapy and Targeted Therapies. Circ Arrhythm Electrophysiol. 2017;10(8):e005443. doi:1161/CIRCEP.117.005443.
  36. Common Terminology Criteria for Adverse Events (CTCAE) v6.0. National Cancer Institute, 2022 (Internet). Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm (accessed04.2023).
  37. Mrotzek S, Lena A, Hadzibegovic S, et al. Assessment of coronary artery disease during hospitalization for cancer treatment. Clin Res Cardiol. 2021;110(2):200–10. doi: 10.1007/s00392-020-01719-5.
  38. Asteggiano R, Aboyans V, Lee G, et al. Cardiology care delivered to cancer patients. Eur Heart J. 2020;41(2):205–6. doi: 10.1093/eurheartj/ehz935.
  39. Aktaa S, Batra G, Wallentin L, et al. European Society of Cardiology methodology for the development of quality indicators for the quantification of cardiovascular care and outcomes. Eur Heart J Qual Care Clin Outcomes. 2022;8(1):4–13. doi: 10.1093/ehjqcco/qcaa069.
  40. Когония Л.М., Русанов М.О., Шикина В.Е. Кардиотоксичность противоопухолевых препаратов и лучевой терапии у пациентов со злокачественными заболеваниями крови и сóлидными злокачественными новообразованиями. Онкогематология. 2022;17(3):127–36. doi: 10.17650/1818-8346-2022-17-3-127-136.
  41. [Kogoniya LM, Rusanov MO, Shikina VE. Cardiotoxicity of anticancer drugs and radiotherapy in patients with hematologic malignancies and solid tumors. Oncohematology. 2022;17(3):127–36. doi: 10.17650/1818-8346-2022-17-3-127-136. (In Russ)]
  42. Nabhan C, Krett N, Gandhi V, et al. Gemcitabine in hematologic malignancies. Curr Opin Oncol. 2001;13(6):514–21. doi: 10.1097/00001622-200111000-00015.
  43. Hilmi M, Ederhy S, Waintraub X, et al. Cardiotoxicity Associated with Gemcitabine: Literature Review and a Pharmacovigilance Study. Pharmaceuticals (Basel). 2020;13(10):325. doi: 10.3390/ph13100325.
  44. Hazam R, Taha A, Kimbugwe J, et al. Gemcitabine-Related Acute Coronary Syndrome. J Med Cases. 2020;11(1):30–3. doi: 10.14740/jmc3417.
  45. Salem J, Manouchehri A, Bretagne M, et al. Cardiovascular Toxicities Associated With Ibrutinib. J Am Coll Cardiol. 2019;74(13):1667–78. doi: 10.1016/j.jacc.2019.07.056.
  46. Francisco A, Alves D, David C, et al. Cardiotoxicity in Hematological Diseases: Are the Tyrosine Kinase Inhibitors Imatinib and Nilotinib Safe? Cardiovasc Toxicol. 2018;18(5):431–5. doi: 10.1007/s12012-018-9453-3.
  47. Singh AP, Umbarkar P, Tousif S, Lal H. Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib. Int J Cardiol. 2020;316:214–21. doi: 10.1016/j.ijcard.2020.05.077.
  48. Fradley M, Groarke J, Laubach J, et al. Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. Br J Haematol. 2018;180(2):271–5. doi: 10.1111/bjh.14970.
  49. Li W, Garcia D, Cornell F, et al. Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review. JAMA Oncol. 2017;3(7):980–8. doi: 10.1001/jamaoncol.2016.3350.
  50. Gavazzoni M, Lombardi CМ, Vizzardi E, et al. Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: Early in vivo cardiovascular effects. Eur J Pharmacol. 2018;838:85–90. doi: 10.1016/j.ejphar.2018.09.014.
  51. Johnson D, Balko J, Compton M, et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med. 2016;375(18):1749–55. doi: 10.1056/NEJMoa1609214.
  52. Hu J, Florido R, Lipson E, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res. 2019;115(5):854–68. doi: 10.1093/cvr/cvz026.
  53. Rubio-Infante N, Ramirez-Flores YА, Castillo EС, et al. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis. Eur J Heart Fail. 2021;23(10):1739–47. doi: 10.1002/ejhf.2289.
  54. Nimwegen F, Schaapveld M, Cutter D, et al. Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma. J Clin Oncol. 2016;34(3):235–43. doi: 10.1200/JCO.2015.63.4444.
Лицензия Creative Commons

Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-ShareAlike» («Атрибуция — Некоммерческое использование — На тех же условиях») 4.0 Всемирная.